Bio-Rad Laboratories (BIO) Stock Insights
BIO$389.16+4.04 +1.05%
$10.41B
Market Cap
46.23
P/E
39.92
Forward P/E
31
Score
Bio-Rad Laboratories (BIO) Stock Insights
BIO price $389.16 +4.04 +1.05%
- Ticker
- BIO
- Price
- $389.16
- Change
- +4.04 +1.05%
- Market cap ?
- $10.41B
- P/E ?
- 46.23
- Forward P/E ?
- 39.92
- Dividend yield ?
- 0.00%
- Beta ?
- 1.07
- Sector
- Healthcare
- Industry
- Medical - Devices
- Stocklytics score
- 31
- Value
- 34
- Quality
- 51
- Growth
- 8
Stocklytics score rationale: value 34, quality 51, growth 8.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 2068172000 | 2160153000 | 2290109000 | 2311659000 | 2545626000 | 2922545000 | 2802249000 | 2671262000 | 2566500000 | 2583200000 |
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing…
Fair value
BIO fair value $229.70. Price $389.16. Price is 69% above fair value.
Above fair value, around its usual premium.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 353.10M. Growth 0.20%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.17% (beta 1.1). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 26.74M. Net debt 999.20M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | 2.23 | — | 649.94M |
| 2026-08-04 | 2.62 | 1.75 | 651.00M | 623.99M |
| 2026-04-30 | 1.89 | 1.97 | 592.10M | 589.91M |
| 2026-02-12 | 2.51 | 2.57 | 693.20M | 688.81M |
| 2025-10-29 | 2.26 | 2.30 | 653.00M | 694.64M |
| 2025-07-31 | 2.61 | 1.93 | 651.60M | 633.81M |
| 2025-05-01 | 2.54 | 1.73 | 585.40M | 573.23M |
| 2025-02-13 | 2.90 | 2.86 | 667.48M | 679.75M |
| 2024-10-30 | 2.01 | 1.28 | 649.73M | 681.29M |
| 2024-08-01 | 3.11 | 2.12 | 638.48M | 645.79M |
| 2024-05-07 | 2.29 | 2.15 | 610.82M | 619.09M |
| 2024-02-15 | 3.10 | 2.93 | 681.18M | 685.09M |
| 2023-10-26 | 2.33 | 2.87 | 632.12M | 689.57M |
| 2023-08-03 | 3.00 | 2.55 | 681.11M | 697.96M |
| 2023-05-04 | 3.34 | 3.24 | 676.84M | 689.83M |
| 2023-02-16 | 3.31 | 3.45 | 730.29M | 742.26M |
| 2022-10-27 | 2.60 | 2.59 | 680.80M | 679.94M |
| 2022-07-28 | 3.38 | 2.46 | 691.10M | 682.62M |
| 2022-04-28 | 4.94 | 2.80 | 700.06M | 672.63M |
| 2022-02-10 | 3.21 | 2.87 | 732.77M | 730.26M |
| 2021-10-28 | 3.71 | 2.30 | 747.05M | 661.87M |
| 2021-07-29 | 3.54 | 1.90 | 715.93M | 545.57M |
| 2021-04-29 | 5.21 | 2.50 | 726.80M | 710.53M |
| 2021-02-11 | 4.01 | 3.10 | 789.84M | 686.80M |
| 2020-10-29 | 3.00 | 1.85 | 647.26M | 533.99M |
| 2020-07-30 | 1.61 | 1.30 | 536.88M | 406.83M |
| 2020-05-06 | 1.91 | 1.40 | 571.64M | 469.89M |
| 2020-02-13 | 2.32 | 2.46 | 624.43M | 656.73M |
| 2019-10-31 | 1.61 | 1.36 | 560.63M | 490.99M |
| 2019-08-01 | 1.57 | 1.39 | 572.62M | 514.97M |
| 2019-05-08 | 1.65 | 1.12 | 553.98M | 372.68M |
| 2019-02-28 | 2.13 | 1.61 | 617.54M | 460.82M |
| 2018-11-01 | 0.91 | 1.16 | 545.14M | 688.86M |
| 2018-08-07 | 1.64 | 1.35 | 575.91M | 445.97M |
| 2018-05-08 | 1.17 | 0.90 | 551.52M | 504.36M |
| 2018-02-27 | 1.50 | 1.28 | 620.43M | 890.76M |
| 2017-11-02 | 0.91 | 0.38 | 535.00M | 223.03M |
| 2017-08-03 | 0.58 | 0.63 | 504.67M | 1.66B |
| 2017-05-04 | 0.42 | 0.30 | 500.05M | 357.21M |
| 2017-02-23 | 1.25 | 1.00 | 571.45M | 840.92M |
Dividends
Yield 0.00%. Payout ratio 22.03%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 22% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-24 | DiVincenzo Jonathan P. | Buy | 1.87K | — | — |
| 2026-10-24 | DiVincenzo Jonathan P. | Sell | 1.87K | — | — |
| 2026-10-24 | DiVincenzo Jonathan P. | Sell | 951 | $369.95 | 351.82K |
| 2026-10-20 | EVRAN SEDAT | Buy | 1.04K | — | — |
| 2026-10-20 | EVRAN SEDAT | Sell | 487 | $354.50 | 172.64K |
| 2026-10-20 | EVRAN SEDAT | Sell | 1.04K | — | — |
| 2026-09-06 | Allison Schwartz | Buy | 92 | — | — |
| 2026-09-06 | Allison Schwartz | Sell | 34 | $386.11 | 13.13K |
| 2026-09-06 | Allison Schwartz | Sell | 92 | — | — |
| 2026-09-06 | BARRY JAMES | Buy | 1.06K | — | — |
| 2026-09-06 | BARRY JAMES | Sell | 1.06K | — | — |
| 2026-09-06 | BARRY JAMES | Sell | 470 | $386.11 | 181.47K |
| 2026-09-06 | EVRAN SEDAT | Buy | 864 | — | — |
| 2026-09-06 | EVRAN SEDAT | Sell | 277 | $386.11 | 106.95K |
| 2026-09-06 | EVRAN SEDAT | Sell | 864 | — | — |
| 2026-09-06 | ENGELHARDT EVA ANETTE | Buy | 1.15K | — | — |
| 2026-09-06 | ENGELHARDT EVA ANETTE | Sell | 1.15K | — | — |
| 2026-09-06 | ENGELHARDT EVA ANETTE | Sell | 485 | $386.11 | 187.26K |
| 2026-09-06 | ENLOE COURTNEY C | Buy | 768 | — | — |
| 2026-09-06 | ENLOE COURTNEY C | Sell | 305 | $386.11 | 117.76K |
| 2026-09-06 | ENLOE COURTNEY C | Sell | 768 | — | — |
| 2026-09-06 | Lakkaraju Roop Kalyan | Buy | 1.54K | — | — |
| 2026-09-06 | Lakkaraju Roop Kalyan | Sell | 782 | $386.11 | 301.94K |
| 2026-09-06 | Lakkaraju Roop Kalyan | Sell | 1.54K | — | — |
| 2026-09-06 | SCHWARTZ NORMAN D | Buy | 3.46K | — | — |
| 2026-09-06 | SCHWARTZ NORMAN D | Sell | 1.85K | $386.11 | 715.85K |
| 2026-09-06 | SCHWARTZ NORMAN D | Sell | 3.46K | — | — |
| 2026-09-05 | Allison Schwartz | Buy | 228 | — | — |
| 2026-09-05 | Allison Schwartz | Sell | 82 | $386.11 | 31.66K |
| 2026-09-05 | Allison Schwartz | Sell | 228 | — | — |
| 2026-09-05 | BARRY JAMES | Sell | 1.03K | — | — |
| 2026-09-05 | BARRY JAMES | Buy | 1.03K | — | — |
| 2026-09-05 | BARRY JAMES | Sell | 369 | $386.11 | 142.47K |
| 2026-09-05 | EVRAN SEDAT | Buy | 1.03K | — | — |
| 2026-09-05 | EVRAN SEDAT | Sell | 1.03K | — | — |
| 2026-09-05 | EVRAN SEDAT | Sell | 329 | $386.11 | 127.03K |
| 2026-09-05 | ENGELHARDT EVA ANETTE | Sell | 1.03K | — | — |
| 2026-09-05 | ENGELHARDT EVA ANETTE | Buy | 1.03K | — | — |
| 2026-09-05 | ENGELHARDT EVA ANETTE | Sell | 369 | $386.11 | 142.47K |
| 2026-09-05 | DiVincenzo Jonathan P. | Sell | 1.71K | — | — |
| 2026-09-05 | DiVincenzo Jonathan P. | Buy | 1.71K | — | — |
| 2026-09-05 | DiVincenzo Jonathan P. | Sell | 668 | $386.11 | 257.92K |
| 2026-09-05 | ENLOE COURTNEY C | Sell | 685 | — | — |
| 2026-09-05 | ENLOE COURTNEY C | Buy | 685 | — | — |
| 2026-09-05 | ENLOE COURTNEY C | Sell | 246 | $386.11 | 94.98K |
| 2026-09-05 | Mehta Rajat | Sell | 1.37K | — | — |
| 2026-09-05 | Mehta Rajat | Buy | 1.37K | — | — |
| 2026-09-05 | Mehta Rajat | Sell | 456 | — | — |
| 2026-09-05 | Mehta Rajat | Sell | 504 | $386.11 | 194.60K |
| 2026-09-05 | Mehta Rajat | Buy | 456 | — | — |
| 2026-09-05 | Mehta Rajat | Sell | 233 | $386.11 | 89.96K |
| 2026-09-05 | Lakkaraju Roop Kalyan | Sell | 1.37K | — | — |
| 2026-09-05 | Lakkaraju Roop Kalyan | Buy | 1.37K | — | — |
| 2026-09-05 | Lakkaraju Roop Kalyan | Sell | 559 | $386.11 | 215.84K |
| 2026-09-05 | SCHWARTZ NORMAN D | Buy | 4.11K | — | — |
| 2026-09-05 | SCHWARTZ NORMAN D | Sell | 2.88K | $386.11 | 1.11M |
| 2026-09-05 | SCHWARTZ NORMAN D | Sell | 4.11K | — | — |
| 2026-09-04 | Allison Schwartz | Buy | 719 | — | — |
| 2026-09-04 | BARRY JAMES | Buy | 4.31K | — | — |
| 2026-09-04 | EVRAN SEDAT | Buy | 4.03K | — | — |
| 2026-09-04 | ENGELHARDT EVA ANETTE | Buy | 4.31K | — | — |
| 2026-09-04 | DiVincenzo Jonathan P. | Buy | 6.33K | — | — |
| 2026-09-04 | ENLOE COURTNEY C | Buy | 2.88K | — | — |
| 2026-09-04 | Mehta Rajat | Buy | 4.60K | — | — |
| 2026-09-04 | Lakkaraju Roop Kalyan | Buy | 6.33K | — | — |
| 2026-09-04 | SCHWARTZ NORMAN D | Buy | 17.25K | — | — |
| 2026-09-01 | BARRY JAMES | Buy | 425 | — | — |
| 2026-09-01 | BARRY JAMES | Sell | 154 | $380.96 | 58.67K |
| 2026-09-01 | BARRY JAMES | Sell | 251 | — | — |
| 2026-09-01 | BARRY JAMES | Sell | 174 | — | — |
| 2026-09-01 | Allison Schwartz | Buy | 117 | — | — |
| 2026-09-01 | Allison Schwartz | Sell | 43 | $380.96 | 16.38K |
| 2026-09-01 | Allison Schwartz | Sell | 75 | — | — |
| 2026-09-01 | Allison Schwartz | Sell | 42 | — | — |
| 2026-09-01 | SCHWARTZ NORMAN D | Buy | 5.09K | — | — |
| 2026-09-01 | SCHWARTZ NORMAN D | Sell | 2.34K | $380.96 | 889.92K |
| 2026-09-01 | SCHWARTZ NORMAN D | Sell | 3.00K | — | — |
| 2026-09-01 | SCHWARTZ NORMAN D | Sell | 2.08K | — | — |
| 2026-07-25 | ENGELHARDT EVA ANETTE | Buy | 246 | — | — |
| 2026-07-25 | ENGELHARDT EVA ANETTE | Sell | 89 | $314.46 | 27.99K |
| 2026-07-25 | ENGELHARDT EVA ANETTE | Sell | 246 | — | — |
| 2026-05-11 | ENGELHARDT EVA ANETTE | Sell | 550 | $246.54 | 135.60K |
| 2026-04-24 | Lakkaraju Roop Kalyan | Buy | 1.08K | — | — |
| 2026-04-24 | Lakkaraju Roop Kalyan | Sell | 420 | $287.84 | 120.89K |
| 2026-04-24 | Lakkaraju Roop Kalyan | Sell | 1.08K | — | — |
| 2026-04-24 | ENLOE COURTNEY C | Buy | 186 | — | — |
| 2026-04-24 | ENLOE COURTNEY C | Sell | 77 | $287.84 | 22.16K |
| 2026-04-24 | ENLOE COURTNEY C | Sell | 186 | — | — |
| 2026-04-21 | Hinckley Greg K | Buy | 407 | — | — |
| 2026-04-21 | Hinckley Greg K | Buy | 369 | — | — |
| 2026-04-21 | Hinckley Greg K | Sell | 407 | — | — |
| 2026-04-21 | PEI MELINDA LITHERLAND | Buy | 407 | — | — |
| 2026-04-21 | PEI MELINDA LITHERLAND | Buy | 369 | — | — |
| 2026-04-21 | PEI MELINDA LITHERLAND | Sell | 407 | — | — |
| 2026-04-21 | EDWARDS JEFFREY L | Buy | 407 | — | — |
| 2026-04-21 | EDWARDS JEFFREY L | Buy | 369 | — | — |
| 2026-04-21 | EDWARDS JEFFREY L | Sell | 407 | — | — |
| 2026-04-21 | PINKSTON ARNOLD A | Buy | 407 | — | — |
| 2026-04-21 | PINKSTON ARNOLD A | Buy | 369 | — | — |
| 2026-04-21 | PINKSTON ARNOLD A | Sell | 407 | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 407, holders +5 vs prior quarter. Ownership 73.30%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FIRST EAGLE INVESTMENT MANAGEMENT, LLC | 2.61M | 3.45K | +0.13% | 765.21M |
| BLACKROCK, INC. | 1.70M | 18.87K | +1.12% | 498.82M |
| DIMENSIONAL FUND ADVISORS LP | 944.55K | -144.78K | -13.29% | 277.33M |
| VANGUARD CAPITAL MANAGEMENT LLC | 826.97K | -4.19K | -0.50% | 242.81M |
| ARIEL INVESTMENTS, LLC | 816.75K | 30.79K | +3.92% | 239.81M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 816.20K | -12.99K | -1.57% | 239.64M |
| EARNEST PARTNERS LLC | 580.75K | -7.98K | -1.36% | 170.51M |
| STATE STREET CORP | 571.76K | 12.19K | +2.18% | 167.88M |
| BANK OF AMERICA CORP /DE/ | 490.41K | 45.45K | +10.22% | 143.99M |
| CAPITAL WORLD INVESTORS | 462.46K | 12.46K | +2.77% | 135.78M |
| CAPITAL RESEARCH GLOBAL INVESTORS | 443.48K | 57.90K | +15.02% | 130.21M |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 418.88K | -7.15K | -1.68% | 122.99M |
| FIRST PACIFIC ADVISORS, LP | 401.86K | -5.50K | -1.35% | 117.99M |
| GEODE CAPITAL MANAGEMENT, LLC | 347.57K | -17.11K | -4.69% | 102.08M |
| NOMURA HOLDINGS INC | 328.90K | 111.56K | +51.33% | 96.57M |
| UBS GROUP AG | 308.32K | -46.04K | -12.99% | 90.53M |
| SEI INVESTMENTS CO | 273.38K | -14.54K | -5.05% | 80.26M |
| BARCLAYS PLC | 267.63K | -11.20K | -4.02% | 78.58M |
| ASSENAGON ASSET MANAGEMENT S.A. | 233.23K | 85.39K | +57.76% | 68.48M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 226.07K | 0 | 0.00% | 66.38M |
| NORTHERN TRUST CORP | 218.28K | -212 | -0.10% | 64.09M |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 195.54K | 195.54K | New | 57.41M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 195.54K | -1.02K | -0.52% | 57.41M |
| FRANKLIN TEMPLETON INC | 193.68K | 23.33K | +13.69% | 56.87M |
| AQR CAPITAL MANAGEMENT LLC | 192.71K | 98.16K | +103.82% | 56.05M |
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2011 | Clinical Diagnostics: 1363800000.0, Life Science: 694700000.0 |
| FY2012 | Clinical Diagnostics: 1365500000.0, Life Science: 688400000.0 |
| FY2013 | Clinical Diagnostics: 1408000000.0, Life Science: 710000000.0 |
| FY2014 | Clinical Diagnostics: 1432300000.0, Life Science: 728300000.0 |
| FY2015 | Clinical Diagnostics: 1310400000.0, Life Science: 695000000.0 |
| FY2016 | Clinical Diagnostics: 1323300000.0, Life Science: 730700000.0 |
| FY2017 | Clinical Diagnostics: 1360800000.0, Life Science: 785200000.0 |
| FY2018 | Clinical Diagnostics: 1411800000.0, Life Science: 861700000.0 |
| FY2019 | Clinical Diagnostics: 1412000000.0, Life Science: 885900000.0 |
| FY2020 | Clinical Diagnostics: 1305200000.0, Life Science: 1231800000.0 |
| FY2021 | Clinical Diagnostics: 1515900000.0, Life Science: 1400800000.0 |
| FY2022 | Clinical Diagnostics: 1451000000.0, Life Science: 1347200000.0 |
| FY2023 | Clinical Diagnostics: 1489300000.0, Life Science: 1178400000.0 |
| FY2024 | Clinical Diagnostics: 1537900000.0, Life Science: 1028100000.0 |
| FY2025 | Clinical Diagnostics: 1562100000.0, Life Science: 1021100000.0 |
| Period | Value |
|---|---|
| FY2011 | Segment, Geographical, Groups of Countries, Group Four: 147700000.0, Segment, Geographical, Groups of Countries, Group One: 896400000.0, Segment, Geographical, Groups of Countries, Group Three: 631000000.0, Segment, Geographical, Groups of Countries, Group Two: 398400000.0 |
| FY2012 | Segment, Geographical, Groups of Countries, Group Four: 149800000.0, Segment, Geographical, Groups of Countries, Group One: 837000000.0, Segment, Geographical, Groups of Countries, Group Three: 656700000.0, Segment, Geographical, Groups of Countries, Group Two: 425700000.0 |
| FY2013 | Segement Geographical Group Europe: 886100000.0, Segment Geographcial Group Pacific Rim: 413300000.0, Segment, Geographical, Groups of Countries, Group Four: 155600000.0, Segment, Geographical, Groups of Countries, Group Three: 677700000.0 |
| FY2014 | Americas: 150900000.0, Asia Pacific: 417500000.0, Europe: 901700000.0, UNITED STATES: 704900000.0 |
| FY2015 | Americas: 128500000.0, Asia Pacific: 392200000.0, Europe: 763700000.0, UNITED STATES: 735000000.0 |
| FY2016 | Americas: 128300000.0, Asia Pacific: 427100000.0, Europe: 742200000.0, UNITED STATES: 770600000.0 |
| FY2017 | Americas: 140200000.0, Asia Pacific: 461300000.0, Europe: 758500000.0, UNITED STATES: 800200000.0 |
| FY2018 | Americas: 138300000.0, Asia Pacific: 495500000.0, Europe: 792000000.0, UNITED STATES: 863600000.0 |
| FY2019 | Americas: 137300000.0, Asia Pacific: 505000000.0, Europe: 770300000.0, UNITED STATES: 899100000.0 |
| FY2020 | Americas: 136600000.0, Asia Pacific: 546500000.0, Europe: 857700000.0, UNITED STATES: 1004800000.0 |
| FY2021 | Americas: 156600000.0, Asia Pacific: 688400000.0, Europe: 946900000.0, UNITED STATES: 1130600000.0 |
| FY2022 | Americas: 155400000.0, Asia Pacific: 639400000.0, Europe: 851900000.0, UNITED STATES: 1155500000.0 |
| FY2023 | Americas: 166600000.0, Asia Pacific: 563000000.0, Europe: 819800000.0, UNITED STATES: 1121900000.0 |
| FY2024 | Americas: 169300000.0, Asia Pacific: 521600000.0, Europe: 834100000.0, UNITED STATES: 1041500000.0 |
| FY2025 | Americas: 165400000.0, Asia Pacific: 513300000.0, Europe: 881800000.0, UNITED STATES: 1022700000.0 |
Insights · Dividends · Forecast · Financials · Learn